Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

ClinicalTrials.gov ID: NCT02899299

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02899299. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.

Study identification

NCT ID: NCT02899299
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 605 participants

Conditions and interventions

Conditions

Mesothelioma

Interventions

Nivolumab Biological
Ipilimumab Biological
Pemetrexed Drug
Cisplatin Drug
Carboplatin Drug

Biological · Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 29, 2016 (Actual)
Primary completion: Mar 25, 2020 (Actual)
Completion: Apr 28, 2023 (Actual)
Last update posted: May 21, 2024

2016 – 2023

United States locations

U.S. sites: 14
U.S. states: 12
U.S. cities: 14

Facility	City	State	ZIP	Site status
Ucsf	San Francisco	California	94143	—
Local Institution - 0014	New Haven	Connecticut	06520	—
H. Lee Moffitt Cancer Center & Research Inst, Inc	Tampa	Florida	33612	—
Local Institution - 0002	Chicago	Illinois	60637	—
Univ Of Maryland Greenbaum Cancer Center	Baltimore	Maryland	21201	—
Local Institution - 0013	Detroit	Michigan	48201	—
Cancer & Hematology Centers Of Western Michigan	Grand Rapids	Michigan	49503	—
Local Institution - 0004	Rochester	Minnesota	55905	—
Memorial Sloan Kettering Nassau	New York	New York	10065	—
Local Institution - 0007	Cleveland	Ohio	44195	—
University Of Pennsylvania	Philadelphia	Pennsylvania	19104	—
Allegheny Cancer Center	Pittsburgh	Pennsylvania	15212	—
Local Institution - 0005	Houston	Texas	77030	—
West Virginia University	Morgantown	West Virginia	26506	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 95 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02899299, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 21, 2024 · Synced Nov 15, 2026